Anti-Tripeptidyl Peptidase-1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody against Tripeptidyl Peptidase-1 (TPP1, UniProt O14773), validated for Western blot; raised against the propeptide domain.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
O14773
Size
100ug
Cat. #
RP2Tripeptidyl Peptidase1

In stock

SKU
RP-Tripeptidyl Peptidase1

Options

As low as: $130.00

Target Overview

Tripeptidyl-peptidase 1 (TPP1; UniProt O14773) is a lysosomal serine protease encoded by the TPP1 gene. The enzyme is synthesised as a ~563-amino-acid zymogen and undergoes autocatalytic activation upon delivery to the acidic lysosomal compartment, where it cleaves tripeptides sequentially from the unsubstituted N-termini of polypeptide substrates (EC 3.4.14.9). This tripeptidyl-peptidase I activity positions TPP1 as a downstream component of lysosomal protein catabolism, acting on the oligopeptide breakdown products generated by upstream lysosomal proteinases such as cathepsins. In addition to its exopeptidase function, TPP1 exhibits endopeptidase activity under certain substrate conditions, though tripeptidyl aminopeptidase activity is considered its primary catalytic role. TPP1 is broadly expressed across human tissues, with particularly high expression in brain, liver, and kidney, consistent with robust lysosomal protein turnover in these organs. Within the cell, the protein localises exclusively to the lysosomal lumen. The zymogen propeptide domain — against which the Triple Point Biologics antibody is raised — serves both as an intramolecular chaperone guiding correct folding and as an autoinhibitory segment preventing premature activation in the secretory pathway. Loss-of-function mutations in TPP1 are the molecular basis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a progressive neurodegenerative lysosomal storage disorder. As a result, TPP1 is widely used as a research target for studying lysosomal biogenesis, autophagy-lysosome pathway dysfunction, and neurodegeneration. Researchers routinely detect TPP1 protein in cell lysates, tissue sections, and neuronal culture models using immunoblot and immunohistochemical approaches.

Background

**Lysosomal Function and Enzymatic Mechanism** TPP1 belongs to the sedolisin family of serine-carboxyl peptidases and is one of a small number of exopeptidases that operate optimally at the acidic pH of the lysosomal lumen (pH ~4.5–5.0). Following synthesis in the endoplasmic reticulum and trafficking through the Golgi via mannose-6-phosphate receptors, the ~66 kDa precursor undergoes autocatalytic removal of its propeptide to yield the mature ~46 kDa active enzyme. Substrate specificity requires a free, unsubstituted N-terminus; the enzyme releases tripeptides processively from polypeptide substrates, complementing the endopeptidase activities of cathepsins B, D, and L in the degradative cascade. This mechanism has been characterised in biochemical detail using fluorogenic substrate panels and site-directed mutagenesis of the catalytic Ser475, Glu272, and Asp360 residues. **CLN2 Disease and Neurodegeneration Research** Biallelic loss-of-function variants in TPP1 cause CLN2 disease (neuronal ceroid lipofuscinosis type 2), a rapidly progressive childhood-onset neurodegenerative lysosomal storage disorder. TPP1 deficiency results in the accumulation of subunit c of mitochondrial ATP synthase and other hydrophobic proteins within autofluorescent lysosomal storage bodies. The cellular consequences of TPP1 knockout — including lysosomal storage accumulation, mitochondrial pathology, and impaired autophagic flux — have been investigated in human neuroblastoma cell models in vitro (Walus et al., 2026, PMID 42102651). Neuroimaging correlates of TPP1 deficiency have been characterised in patient cohorts, including prospective studies mapping brain atrophy progression in CLN2 patients (Petersen et al., 2026, PMID 42175674) and descriptive analyses of neuroimaging and molecular findings across neuronal ceroid lipofuscinosis subtypes (Rahimian et al., 2026, PMID 42283952). **Broader Research Context** Beyond monogenic CLN2 disease, TPP1 has been studied as a research target in the broader context of lysosomal stress responses and cancer cell biology. Transcriptomic analyses have identified TPP1 among endoplasmic reticulum stress-related gene signatures in neuroblastoma, suggesting a potential role in proteostatic stress responses in tumour cells (Lu et al., 2026, PMID 42180899). TPP1 orthologues have also been identified and functionally characterised in bacterial systems, reflecting conserved structural features of the sedolisin protease fold (Yang et al., 2026, PMID 42264755). Together, these lines of inquiry make TPP1 a well-validated immunoblot and immunohistochemical target across neurological, cellular, and comparative biology research programmes.

References

  1. Rahimian E et al. Exploratory Analysis of Neuroimaging and Molecular Findings in a Cohort of Neuronal Ceroid Lipofuscinosis: a Descriptive study. J Mol Neurosci. 2026. doi:10.1007/s12031-026-02553-6. PMID: 42283952.
  2. Yang P et al. Identification and functional analysis of two novel tpp genes in Bacillus thuringiensis HSY91. Pestic Biochem Physiol. 2026. doi:10.1016/j.pestbp.2026.107157. PMID: 42264755.
  3. Lu W et al. Identification and analysis of endoplasmic reticulum stress-related genes in neuroblastoma and construction of a prognostic gene signature. Transl Cancer Res. 2026. doi:10.21037/tcr-2025-1-2623. PMID: 42180899.
  4. Petersen M et al. Mapping Clinical Progression to Brain Atrophy in CLN2 Patients Under Cerliponase Alfa Treatment: A Prospective Neuroimaging Study. J Inherit Metab Dis. 2026. doi:10.1002/jimd.70202. PMID: 42175674.
  5. Walus M et al. Lysosomal storage, mitochondrial pathology, and autophagy in knockout of tripeptidyl peptidase 1 in human neuroblastoma cells in vitro. Mol Genet Metab. 2026. doi:10.1016/j.ymgme.2026.110130. PMID: 42102651.

Additional Specifications

Gene Symbol TPP1
UniProt ID O14773
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 20-195.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 199-563.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 513-563.

Frequently Asked Questions

What molecular weight band should I expect for TPP1 on a Western blot?

TPP1 is synthesised as a ~61 kDa proenzyme and undergoes proteolytic maturation in the lysosome. On Western blot, you typically observe the mature form at approximately 46 kDa, which represents the catalytically active enzyme. Depending on cell type and lysosomal processing efficiency, you may also detect the proenzyme or intermediate processing forms around 50-61 kDa. Glycosylation heterogeneity can cause band broadening. If you see multiple bands, this often reflects normal maturation rather than non-specific binding. Run a positive control lysate from a cell line with high lysosomal content to establish your expected pattern.

What starting dilution should I use for Western blot with this TPP1 antibody?

The recommended starting dilution for Western blot is 1:1000 in blocking buffer. This polyclonal antibody has been validated at this concentration for detecting endogenous TPP1 in human cell lysates. Depending on your sample TPP1 expression level, you may need to titrate between 1:500 and 1:2000. Lysosome-enriched fractions or tissues with high lysosomal content may yield stronger signal and permit higher dilution. Always include a lysate known to express TPP1 as a positive control during your initial titration to confirm antibody performance in your specific blocking and detection system.

Is this antibody validated for detecting TPP1 in species other than human?

This antibody has been validated specifically for human TPP1. Cross-reactivity with mouse or rat TPP1 is predicted based on sequence homology in the immunogen region, but has not been experimentally validated by Triple Point Biologics. If you are working with non-human samples, we recommend running a pilot blot alongside human positive control lysate to confirm detection. Sequence alignment of the epitope region against your species of interest can help predict likely reactivity, but empirical testing remains the definitive approach. Contact us if you obtain cross-species data we can add to the validation record.

Can I use this TPP1 antibody for immunofluorescence or immunohistochemistry?

Triple Point Biologics antibodies are routinely validated for Western blot and immunohistochemistry as brand-wide applications. This rabbit polyclonal should be compatible with IHC on formalin-fixed paraffin-embedded tissue sections and immunofluorescence in cultured cells, though specific validation data for TPP1 in those formats are not yet available. For IF, start around 1:100-1:200 dilution; for IHC, typical working dilutions range from 1:50 to 1:200 depending on antigen retrieval method. Because TPP1 is lysosomal, expect punctate perinuclear staining. Titrate carefully and include a no-primary-antibody control to assess background in your system.

What sample preparation considerations are important for detecting lysosomal TPP1?

TPP1 is a soluble lysosomal hydrolase, so standard RIPA or NP-40 lysis buffers work well for whole-cell lysates. Include protease inhibitors to prevent degradation, though TPP1 itself is relatively stable. If you are fractionating, TPP1 partitions with the lysosome-enriched pellet in differential centrifugation but is released into the supernatant upon lysosomal lysis. Avoid prolonged incubation at acidic pH during lysis, as this may trigger autocatalytic processing or activity that complicates band interpretation. For tissue samples, fresh-frozen material generally yields cleaner results than aged or improperly stored specimens due to TPP1's role in protein catabolism.

Does TPP1 have isoforms or splice variants I should be aware of?

The TPP1 gene produces a single major transcript encoding the 563-amino-acid preproenzyme. Alternative splicing has not been widely reported for TPP1, so you should expect one principal isoform. The complexity you observe on a blot typically arises from post-translational processing rather than splice variants: the proenzyme is N-glycosylated in the ER, trafficked to lysosomes, and proteolytically cleaved to generate the mature enzyme. Loss of signal or aberrant processing patterns can occur in cells with lysosomal storage defects or trafficking mutations. If working with patient-derived samples, be aware that pathogenic TPP1 mutations underlie neuronal ceroid lipofuscinosis type 2.

How should I store this TPP1 antibody and what is the expected shelf life?

Store the antibody at -20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The 100 µg pack size is suitable for aliquoting into 10-20 µL volumes depending on your typical usage. Polyclonal antibodies in glycerol-containing storage buffer are generally stable for at least two years at -20°C. For short-term use, a working aliquot can be kept at 4°C for up to one month. Avoid leaving the antibody at room temperature for extended periods. If you observe increased background or loss of signal over time, prepare a fresh aliquot rather than continuing with a degraded stock.

What positive control cell line or tissue should I use to validate TPP1 detection?

Most mammalian cell lines express detectable TPP1 because it is a constitutive lysosomal protease involved in housekeeping protein catabolism. HeLa, HEK293, and fibroblast lysates serve as reliable positive controls. Tissues rich in lysosomes such as liver, spleen, or kidney homogenates typically show robust TPP1 signal. If you are studying a disease model, compare your experimental sample against a wild-type or non-diseased control processed identically. For assay development, consider obtaining a characterized reference lysate or recombinant TPP1 fragment to confirm antibody specificity before moving to experimental samples with unknown expression levels.

Validation imagery coming soon

Western blot validation figures for RP-Tripeptidyl Peptidase1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →